Database : HANSEN
Search on : CLOFAZIMINA/USO TERAP [Subject descriptor]
References found : 61 [refine]
Displaying: 1 .. 20   in format [Detailed]

page 1 de 4 go to page            

  1 / 61 HANSEN  
              next record last record
select
to print
Texto Completo-en
Id:19754
Author:Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M.
Title:Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Source:Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab.
Abstract: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien.
Descriptors:Clofazimina/admin
Clofazimina/uso terap
Dapsona/admin
Dapsona/uso terap
Hanseníase Dimorfa/microbiol
Hanseníase Virchowiana/microbiol
Limits:Humanos
Adolescente
Adulto
Electronic Medium:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf / en
Location:Br191.1


  2 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18390
Author:Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K
Title:Drug resistant-Mycobacterium leprae- results of mouse footpad studies from a laboratory in South India ..-
Source:s.l; s.n; 2002. 12 p. tab.
Abstract:Out of 265 biopsies of leprosy patients received at the Experimental Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae using the mouse footpad technique, 49 showed resistant strains of M. leprae to varying concentration of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resitance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistent strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emplasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community (AU).
Descriptors:MYCOBACTERIUM LEPRAE/cresc
MYCOBACTERIUM LEPRAE/isol
MYCOBACTERIUM LEPRAE/metab
MYCOBACTERIUM LEPRAE/patogen
MYCOBACTERIUM LEPRAE/ultraest
RESISTÊNCIA A DROGAS
DAPSONA/uso terap
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
TESTES DE SENSIBILIDADE MICROBIANA/métodos
TESTES DE SENSIBILIDADE MICROBIANA/vet
HANSENIASE/clas
 HANSENIASE/compl
 HANSENIASE/quimioter
 HANSENIASE/imunol
 HANSENIASE/microbiol
 HANSENIASE/patol
 OFLOXACINO/uso terap
 MINOCICLINA/uso terap
Limits:HUMANO
Location:BR191.1; 09299/s


  3 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18385
Author:Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong
Title:Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..-
Source:s.l; s.n; 2000. 3 p. tab.
Abstract:Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU).
Descriptors:HANSENIASE/quimioter
HANSENOSTATICOS/admin
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/farmacocin
HANSENOSTATICOS/uso terap
MYCOBACTERIUM LEPRAE
TESTES DE SENSIBILIDADE MICROBIANA/métodos
DROGAS EM INVESTIGACAO/admin
DROGAS EM INVESTIGACAO/anal
DROGAS EM INVESTIGACAO/uso terap
BACTERICIDAS
 QUIMIOTERAPIA COMBINADA
 MYCOBACTERIUM LEPRAE/metab
 MYCOBACTERIUM LEPRAE/fisiol
 DAPSONA/uso terap
 RIFAMPINA/uso terap
 CLOFAZIMINA/uso terap
 OFLOXACINO/uso terap
 MINOCICLINA/uso terap
 CLARITROMICINA/uso terap
Limits:ESTUDO COMPARATIVO
Location:BR191.1; 09311/s


  4 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18384
Author:Biswas, S; Mondal, K. K
Title:Multidrug therapy in leprosy can prevent relapse- a retrospective study ..-
Source:s.l; s.n; 2002. 6 p. .
Abstract:A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU).
Descriptors:HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/prev
RECIDIVA/prev
HANSENOSTATICOS/admin
 HANSENOSTATICOS/hist
 HANSENOSTATICOS/normas
 HANSENOSTATICOS/uso terap
 CLOFAZIMINA/uso terap
 DAPSONA/uso terap
 RIFAMPINA/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:BR191.1; 09310/s


  5 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18294
Author:Wood, Leonard
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy: I- The response to therapy as measured by inoculation of mice ..-
Source:s.l; s.n; 1978. 10 p. tab.
Abstract:Two recent trials of chemotherapy in relatively large numbers of patients with lepromatous leprosy generated data that permitted analysis of the effects of treatment regimens and of various pretreatment characteristics of the patients. The results of treatment were measured by inoculation of mice with Mycobacterium leprae recovered from skin biopsy specimens obtained from the patients at intervals during the trials. The pretreatment variables-sex, age histopathological and clinical classifications, logarithmic biopsy specimen (LAFB) - were found to be uniformly distributed among the 36 patients treated by regimens 1, 2, 4 and 5 of trial I. . The ten patients treated by regimen 3 were excluded from this analysis. These pretreatment variables were also found to be uniformly distributed among all 21 patients treated by the two regimens of trial II...(AU).
Descriptors:HANSENIASE VIRCHOWIANA/clas
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE VIRCHOWIANA/fisiopatol
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:ESTUDO COMPARATIVO
Location:BR191.1; 0296/S


  6 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18229
Author:Leonard Wood Memorial*.
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables ..-
Source:s.l; s.n; 1978. 4 p. tab.
Abstract:Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU).
Descriptors:HANSENIASE DIMORFA/terap
HANSENIASE VIRCHOWIANA/terap
CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
DAPSONA/uso terap
HANSENIASE DIMORFA/microbiol
HANSENIASE DIMORFA/patol
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
QUIMIOTERAPIA COMBINADA
 DROGAS EM INVESTIGACAO/admin
 DROGAS EM INVESTIGACAO/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:BR191.1; 00294/s


  7 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:18090
Author:Sampaio, Sebastiao AP; Rivitti, Evandro A.
Title:Hanseníase / Leprosy
Source:In: Sampaio, Sebastiao AP; Rivitti, Evandro A.Dermatologia. Sao Paulo, Artes Medicas, 2007. p.625-651ilus, graf.
Descriptors:HANSENIASE/imunol
HANSENIASE/microbiol
HANSENIASE/prev
HANSENIASE/fisiopatol
HANSENIASE/reabil
HANSENIASE/terap
MYCOBACTERIUM LEPRAE/citol
MYCOBACTERIUM LEPRAE/genet
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/fisiol
ANTIGENO DE MITSUDA/quim
ANTIGENO DE MITSUDA/fisiol
RIFAMPINA/farmacol
 RIFAMPINA/uso terap
 DAPSONA/farmacol
 DAPSONA/uso terap
 CLOFAZIMINA/farmacol
 CLOFAZIMINA/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:Br191.1; WR100, S47d


  8 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:17453
Author:Wood, L
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy ?-
Source:s.l; s.n; 1978. 4p p. .
Abstract:Interrelationships among six patient characteristics recorded upon entry into the trial were analyzed for 67 patients with lepromatous and near-lepromatous leprosy admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of other patients and of patients classified as bordeline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological ground were classified fully lepromatous by the clinical criteria. Measurementd of the number of Mycobacterium leprae in the patients made by three methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the one hand, and any of the measurements of the numbers of organisms on the other.
Descriptors:HANSENIASE VIRCHOWIANA/clas
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:RELATO DE CASO
Location:BR191.1; 00294/s; BR191.1; 00295/s


  9 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:17389
Author:Avelleira, Joao Carlos Regazzi.
Title:Tratamento da hanseniase / ?
Source:In: Rio de Janeiro (Estado). Secretaria da Saude.Curupaiti em Revista. Rio de Janeiro, s.n, 2002. p.24-27ilus.
Abstract:O controle da hanseniase e considerado uma das prioridades da OMS, por ser uma endemia com potencial incapacitante importante. Os autores fazem uma revisao do tratamento da hanseniase desde a utilizacao do oleo de chaulmugra em 1854, passando pela introducao da sulfona em 1941, ao aparecimento da resistencia secundaria e primaria a sulfona, razao da associacao de outras drogas no tratamento da doenca. O esquema dividia os pacientes em multibacilares e paucibacilares, usando regimes com tres drogas (Rifampicina, Clofazimina e Dapsona) para as formas multibacilares e duas drogas (Rifampicina e Sulfona) para os paucibacilares. Foram realizadas mudancas na duracao do tratamento, e novas drogas como as quinolonas, claritromicina e minociclina mostraram eficacia contra o M. leprae possam ser utilizadas em esquemas alternativos. (AU).
Descriptors:HANSENIASE/prev
TERAPÊUTICA
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:RELATO DE CASO
Location:BR191.1; 01114/d.a


  10 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13628
Author:Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo
Title:Biochemical and hematological side effects of clofazimine in leprosy patients ..-
Source:s.l; s.n; 2002. 4 p. tab.
Abstract:Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU).
Descriptors:CONTAGEM DE CELULAS SANGUINEAS
CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/ef adv
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/ef adv
RIFAMPINA/uso terap
Limits:SUPPORT, NON-U.S. GOV'T
FEMININO
HUMANO
MASCULINO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 08998/s


  11 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13608
Author:Yawalkar, S. J; Vischer, W
Title:Lamprene (clofazimine) in leprosy ..-
Source:s.l; s.n; jun. 1979. 10 p. graf.
Abstract:We are extremely grateful to CIBA-GEIGY Limited for permission to reproduce in full this 15-page booklet on a drug of increasing interest and value in the treatment of leprosy.(AU).
Descriptors:CLOFAZIMINA/ef adv
CLOFAZIMINA/metab
CLOFAZIMINA/uso terap
HANSENIASE/quimioter
QUIMICA
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01138/s


  12 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13605
Author:Binford, Chapman H; Meyers, Wayne M; Walsh, Gerald P
Title:Leprosy ..-
Source:s.l; s.n; April 23, 1982. 10 p. ilus, mapas, graf.
Abstract:TODAY, leprosy impairs the physical, social, and economic well-being of millions. Those who live in Third World countries suffer most, because living conditions are marginal and health care provision systems are undeveloped or disrupted by political ferment.(AU).
Descriptors:CERCOPITHECIDAE
CLOFAZIMINA/uso terap
MODELOS ANIMAIS DE DOENCAS
HANSENIASE/epidemiol
HANSENIASE/terap
HANSENIASE/transm
MYCOBACTERIUM LEPRAE/isol
PAN TROGLODYTES
PELE/microbiol
SULFONAS/uso terap
TEMPERATURA AMBIENTE
 ESTADOS UNIDOS
Limits:ANIMAL
HAMSTERS
CAMUNDONGOS
RATOS
TATUS
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00560/s


  13 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13591
Author:Ffytche, T. J; McDougall, A. C
Title:Leprosy and the eye: a review ..-
Source:s.l; s.n; may 1985. 4 p. tab.
Abstract:There is no longer any indigenous leprosy in the United Kingdom, and in Europe generally the incidence of this disease has fallen to low levels. But in the world at large it is estimated by WHO that there are nearly 10.5 million cases, of whom only about 5 million have so far been detected, diagnosed and registered for treatment (Sansarricq 1981).(AU).
Descriptors:HANSENIASE/compl
HANSENIASE/quimioter
HANSENIASE/prev
MYCOBACTERIUM LEPRAE/imunol
DAPSONA/uso terap
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
Limits:HUMANO
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01821/s


  14 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13558
Author:Hooper, M; Purohit, M. G
Title:The chemotherapy of leprosy ..-
Source:s.l; s.n; 1983. 81 p. ilus, tab, graf.
Abstract:This review presents a critical assessment of the chemotherapy of leprosy referring to both ancient and more recent drugs. In the light of the growing understanding of Mycobacterium leprae and the disease of leprosy, suggestions are made about possible ways new drugs might de developed.(AU).
Descriptors:CLOFAZIMINA/uso terap
HANSENOSTATICOS/uso terap
HANSENIASE/diag
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE
RIFAMICINAS/uso terap
SULFONAS/uso terap
Limits:HUMANO
ANIMAL
CAMUNDONGOS
RATOS
SUPPORT, NON-U.S. GOV'T
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01722/s


  15 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13532
Author:Anon
Title:Leprosy ..-
Source:s.l; s.n; 2001. 3 p. .
Abstract:Leprosy is a chronic disease caused by a bacillus, Mycobacterium leprae. - M. leprae multiplies very slowly and the incubation period of the disease is about five years. Symptom can take as long as 20 years to appear. (AU).
Descriptors:CLOFAZIMINA/uso terap
ANALISE CUSTO-BENEFICIO
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
COOPERACAO INTERNACIONAL
MYCOBACTERIUM LEPRAE/isol
MICOBACTERIOSE/quimioter
MICOBACTERIOSE/epidemiol
PREVALÊNCIA
HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENOSTATICOS/uso terap
RIFAMPINA/uso terap
SAUDE MUNDIAL
ORGANIZACAO MUNDIAL DA SAUDE
Limits:HUMANO
Location:BR191.1; 08980/s


  16 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13354
Author:Holmes, I. B; Banerjee, D. K; Hilson, G. R
Title:Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection ..-
Source:s.l; s.n; apr. 1976. 5 p. graf.
Abstract:Continuous dietary administration of rifampin to mice with an established Mycobacterium leprae footpad infection reduced the bacillary solid ratio, with an estimated survival half-life of 5-6 days. In rifampin-treated immunosuppressed animals the survival half-life of solid bacilli, in the absence of host immunity, was 12-13 days. Clofazimine and B1912 produced a significant effect on solid ratio only after a lag period of apparently 100 days. The rate of action was considerably slower than that of rifampin. Intermittent (once monthly) administration of both drugs produced effects similar to those of continuous administration.(AU).
Descriptors:ANTICORPOS ANTIBACTERIAS
CLOFAZIMINA/analog
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
IMUNOSSUPRESSAO
HANSENIASE/quimioter
HANSENIASE/imunol
MYCOBACTERIUM LEPRAE/ef drogas
MYCOBACTERIUM LEPRAE/imunol
FATORES DE TEMPO
RIFAMPINA/farmacol
RIFAMPINA/uso terap
Limits:ESTUDO COMPARATIVO
ANIMAL
CAMUNDONGOS
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 01652/s


  17 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13340
Author:Jakes, James T; Dubois, Edmund L; Junior Quismorio, Francisco P
Title:Antileprosy drugs and lupus erythematosus ..-
Source:s.l; s.n; 1982. 01 p. .
Abstract:We read with interest the article the dramatic response to dapsone therapy...(AU).
Descriptors:LUPUS ERITEMATOSO DISCOIDE/quimioter
LUPUS ERITEMATOSO SISTÊMICO/quimioter
CLOFAZIMINA/uso terap
DAPSONA/uso terap
Limits:HUMANO
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00996/s


  18 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13310
Author:Dubey, G. K; Joglekar, V. K; Hardas, U. D; Chaubey, B. S
Title:A study of cell mediated immunity in leprosy ..-
Source:s.l; s.n; apr. 1981. 7 p. tab, graf.
Abstract:This paper presents a review of 123 cases of leprosy of different clinical types as regards to their status of cellular immunity. These 123 cases included 41 fresh cases, 18 cases of reaction and 64 cases of leprosy taking antileprosy treatment. Out of 41 untreated cases only 11 turned up for follow up and their lymphoblastic transformation was repeated 4 to 6 months after initiating the treatment. It was observed that cell mediated immunity as expressed in terms of percentage of blast cells is definitely depressed in leprosy, most in LL and least in TT. There is a definite increase in the percentage of blast cells after taking antileprosy treatment. The rise in percentage of blast cells and hence cellular immunity is relatively more in patients treated with Lamprene as compared to those treated with DDS. Reactions also have impact over immunity in leprosy. Thus, most of the patients with ENL show higher values for blast percentage as compared to those with lepra reaction. It appears that serial lymphocyte cultures if done in all cases of leprosy undergoing treatment will help in assessment of individual progress.(AU).
Descriptors:IMUNIDADE CELULAR/ef drogas
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
HANSENIASE/imunol
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
DAPSONA/farmacol
DAPSONA/uso terap
Limits:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
ADOLESCENTE
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00771/s


  19 / 61 HANSEN  
              first record previous record next record last record
select
to print
Id:13299
Author:Kundu, S. K; Ghosh, S; Hazra, S; Chaudhury, S
Title:Multiple drug therapy--a comparative study with 2 tier and 3 tier combination of rifampicin, clofazimine, DDS, INAH and thiacetazone in lepromatous cases ..-
Source:s.l; s.n; apr. 1981. 11 p. tab.
Abstract:A comparative study with 2 tier and 3 tier combination of Rifampicin, Clofazimine, DDS, INAH and Thiacetazone was conducted on fifty lepromatous leprosy cases for varying periods. Assessment showed that 2 tier combination of clofazimine and DDS produced good results but the cost stood in the way; whereas 3 tier combination of DDS, thiacetazone and INAH also yielded good results with much less expenses to be incurred by the patients. Whether therapy with this 3 tier combination could be continued for a longer period with sustained improvement is yet to be assessed by further studies for a considerable period.(AU).
Descriptors:HANSENIASE/quimioter
ISONIAZIDA/uso terap
RIFAMPINA/uso terap
TIOACETAZONA/uso terap
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
CLOFAZIMINA/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
ADOLESCENTE
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00695


  20 / 61 HANSEN  
              first record previous record
select
to print
Id:13224
Author:Bourée, P; Carré, N; Drahmane, S
Title:Guinée: dépistage de la lèpre et traitement par polychimiothérapie Guinea: detection of leprosy and treatment by polychemotherapy-
Source:s.l; s.n; 1988. 9 p. mapas, tab.
Abstract:Since a year, the implementation of multidrug therapy on leprosy control in Guinea has been needing a good cooperation between Department of Leprosy Control and local nurses. The known prevalence, in the area of Pita is 1.23%. 246 patients has been detected: 36 multibacillary and 210 paucibacillary. The sex-ratio of the patients has changed, during one year, toward the men. With the sensitivity of the local population, number of detected cases is increasing and the rate of regular attendance at treatment is correct in 87.6% of cases.(AU).
Descriptors:HANSENIASE/quimioter
HANSENIASE/epidemiol
RIFAMPINA/admin
RIFAMPINA/uso terap
AFRICA OCIDENTAL
CLOFAZIMINA/admin
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
Limits:HUMANO
MASCULINO
FEMININO
RESUMO EM INGLES
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 02055/s



page 1 de 4 go to page            
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information